Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of ...

Researchers at the University of Glasgow have received £399,670 in funding from Breast Cancer Now and Secondary1st to develop ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase ...

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...

Space infrastructure company Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it has been awarded a contract from Aspera Biomedicines, Inc. (Aspera), a ...